Press Releases

− Proceeds to support Recursion’s development of its broad clinical-stage pipeline and expansion of the capabilities of its drug discovery platform − − Series D financing led by Leaps by Bayer and supported by a consortium of new and existing healthcare and technology investors − SALT LAKE CITY,

- Drug discovery partnership and equity investment led by Leaps by Bayer in Series D financing round - Digitally-powered drug discovery to address fibrotic diseases with previously undiscovered mechanisms and to deliver novel therapies to patients faster Berlin, Germany and Salt Lake City, USA,

SALT LAKE CITY--( BUSINESS WIRE )--Recursion, a digital biology™ company leading in the industrialization of drug discovery, today announced its acquisition of Vium, a digital vivarium™ company. Vium’s platform combines computer vision, machine learning and sensor technologies to non-invasively

More than 305,000 high-resolution, multi-channel COVID-19 cellular images captured in less than four weeks with Molecular Devices ImageXpress® Micro Confocal High-Content Imaging System are now available to the scientific community. SAN JOSE, Calif. – June 25, 2020 — With the COVID-19 pandemic

SALT LAKE CITY, Nov. 8, 2018 / PRNewswire / --  Recursion Pharmaceuticals , a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, today announced a $1.6 million Phase 2 Small Business Innovation Research

Award coincides with the opening of Recursion's expansive new R&D facility SALT LAKE CITY, Nov. 5, 2018 / PRNewswire / --  Recursion Pharmaceuticals , a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, has

SALT LAKE CITY, July 10, 2018 / PRNewswire / --  Recursion , a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, today announced the company has appointed Tina M. Larson as Chief Operating Officer.

SALT LAKE CITY, July 10, 2018 / PRNewswire / --  Recursion , a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover drugs at scale, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug

SALT LAKE CITY, May 15, 2018 / PRNewswire / --  Recursion Pharmaceuticals , a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover drugs at scale, today announced that it has hired Phil Carpino, Ph.D.

The grant, awarded by the Bill & Melinda Gates Foundation, represents a collaborative effort between Recursion and the Winzeler Lab at UC San Diego School of Medicine to accelerate the discovery of drugs to treat malaria, and sets the stage for Recursion to further broaden its drug discovery